Seegene, BD Collaborate To Develop Multiplex Molecular Diagnostic Assays

Seegene Inc., a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics, and BD Life Sciences, a segment of Becton, Dickinson and Co. (BDX) have entered into a worldwide collaboration agreement to co-develop multiplex real-time PCR reagents for the BD MAX System.

Under the terms of the agreement, Seegene will develop and manufacture multiplex tests based on novel DPO, TOCE, and MuDT technologies designed exclusively for BD's molecular diagnostics platform.

BD, in turn, will have worldwide commercialization rights to these tests.

The BD MAX System offers an efficient path to improved clinical outcomes by combining and automating real-time PCR extraction, amplification and detection into a single platform that can run a wide range of assays across multiple disease states. This will enable physicians to address a wide breadth of testing needs.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT